Peptide directory

A synthetic heptapeptide derived from tuftsin, characterised in Russian research literature for anxiolytic and neuroimmune effects.

A heptapeptide analog of adrenocorticotropic hormone fragment 4–10, developed as a nootropic and neuroprotective peptide in Russian research programmes.

The short-acting variant of CJC-1295 — a GHRH(1-29) analog with four amino-acid substitutions for degradation resistance but without the maleimidopropionic-acid moiety that produces albumin binding. Half-life on the order of 30 minutes, in contrast to the DAC version's multi-day exposure.

A growth-hormone-releasing hormone (GHRH) analogue with a maleimide (Drug Affinity Complex) linker that binds serum albumin, extending its circulating half-life to several days.

A synthetic hexapeptide growth-hormone secretagogue that acts at the ghrelin receptor (GHS-R1a) with reported cardiovascular activity in addition to GH release.

A pentapeptide growth-hormone secretagogue that binds the ghrelin/GHS-R1a receptor, reported as one of the most selective GH-releasers with minimal effect on cortisol or prolactin.

The 29-amino-acid N-terminal fragment of endogenous growth-hormone-releasing hormone. Historically approved as Geref for paediatric growth-hormone-deficiency diagnostics.

A stabilised GHRH analog carrying a trans-3-hexenoyl group at the N-terminus, protecting against dipeptidyl-peptidase-IV cleavage. FDA-approved in 2010 as Egrifta for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.

A synthetic 15-amino-acid peptide fragment derived from a protein found in gastric juice. Studied extensively in animal models for tissue repair, gut-barrier integrity, and tendon/ligament healing.

The C-terminal tripeptide of alpha-melanocyte stimulating hormone. Characterised across inflammatory-bowel, dermatology, and general anti-inflammatory research literature.

A synthetic peptide related to Thymosin Beta-4, a naturally occurring actin-sequestering protein. Studied in animal models for wound healing, cardiac regeneration, and hair-follicle biology.

A 28-amino-acid acetylated peptide derived from prothymosin alpha, characterised in immunological research and approved in several countries under the brand name Zadaxin.

A synthetic tetrapeptide derived from pineal-gland extract characterised in Russian gerontology research for telomerase-related and geroprotective effects.

An investigational D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction and selectively induce apoptosis in senescent cells. Characterised in mice; no published human clinical trials.

A 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene, characterised in research on mitochondrial signalling, metabolic homeostasis, and exercise biology.

Nicotinamide adenine dinucleotide is a small-molecule cofactor rather than a peptide, but it is commonly grouped with longevity peptides and included here for reference. Studied for effects on cellular energy metabolism and sirtuin signalling.

A cationic, mitochondria-targeting tetrapeptide that concentrates at the inner mitochondrial membrane and binds cardiolipin. Investigational; developed for mitochondrial dysfunction — most advanced clinically in Barth syndrome.

A 16-amino-acid modified fragment of the C-terminus of human growth hormone (residues 176–191) with an added N-terminal tyrosine, characterised as a lipolytic peptide.

An investigational triple agonist at the glucagon, GIP, and GLP-1 receptors currently in phase-3 obesity and metabolic research programmes.

A long-acting GLP-1 receptor agonist. Approved by regulators in branded clinical formulations for type 2 diabetes and chronic weight management; described here for scientific reference only.

An investigational once-weekly dual glucagon (GCGR) and glucagon-like-peptide-1 (GLP-1R) receptor co-agonist being developed by Boehringer Ingelheim and Zealand Pharma. Not FDA-approved.

A dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has been characterised in metabolic and body-weight research at reference doses of 2.5–15 mg per week.

A cyclic heptapeptide melanocortin-receptor agonist studied in sexual-health research and approved in the United States under the brand name Vyleesi for a specific indication.

A naturally occurring copper-binding tripeptide characterised in the research literature for effects on skin remodelling, wound repair, and hair-follicle biology.

A cyclic heptapeptide analog of alpha-melanocyte stimulating hormone that has been characterised in the pigmentation-research literature. Precursor to the marketed melanocortin-4 agonist bremelanotide.

An octapeptide cosmetic ingredient (acetyl octapeptide-3) developed as an extension of the SNARE-competitive hexapeptide Argireline. Used topically in anti-wrinkle formulations; no established injectable use in the research literature.

A nonapeptide originally isolated from rabbit brain during electrophysiological sleep-induction experiments; characterised in the sleep, stress, and neuroendocrine research literature.